Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 559654

Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience


Pejša, Vlatko; Prka, Željko; Lucijanić, Marko; Jakšić, Ozren; Piršić, Mario; Ajduković, Radmila; Kušec, Rajko
Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience // Abstracts of the Leukemia and Lymphoma Meeting "East and west are together"
Dubrovnik, Hrvatska, 2011. (poster, nije recenziran, sažetak, znanstveni)


CROSBI ID: 559654 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience

Autori
Pejša, Vlatko ; Prka, Željko ; Lucijanić, Marko ; Jakšić, Ozren ; Piršić, Mario ; Ajduković, Radmila ; Kušec, Rajko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the Leukemia and Lymphoma Meeting "East and west are together" / - , 2011

Skup
Leukemia and Lymphoma Meeting "East and west are together"

Mjesto i datum
Dubrovnik, Hrvatska, 17.09.2011. - 21.09.2011

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
NHL; DA-EPOCH; high risk

Sažetak
In this report we presented 22 patients with high risk diffuse large B-cell lymphoma. Our results showed that DA-EPOCH-R is highly effective regimen in this group of patients. These results are conclusive with results of Garcia-Suarez and colleagues (Garcia-Suarez J et al. British journal of Haematology 2007 ; 136:276-285) who also find this regimen effective as first line treatment in DLBCL patients. Some of our patients were consolidated with autoHSCT due to high proliferation index or IPI≥3. Only 1 patient relapsed during follow up period. Of 6 patients who were transplated, all but one are still in CR. We conclude that DA-EPOCH-R is highly effective regimen as first line treatment in high risk diffuse large B-cell lymphoma.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Rad je kao predavanje prezentiran i na skupu 16th Congress of EHA, održanom od 09-12.06.2011., London, Velika Britanija.



POVEZANOST RADA


Projekti:
108-1980955-3094 - Genetika i funkcija hematopoeze i mikrookoliša Ph- mijeloproliferativnih bolesti (Kušec, Rajko, MZOS ) ( CroRIS)
198-1980955-0953 - Imunobiologija kronične B-limfocitne leukemije i mikrookoliš (Jakšić, Ozren, MZOS ) ( CroRIS)
198-1980955-0954 - Novi klinički pristupi kroničnim mijelo i limfoproliferacijama (Pejša, Vlatko, MZOS ) ( CroRIS)

Ustanove:
Klinička bolnica "Dubrava"

Profili:

Avatar Url Rajko Kušec (autor)

Avatar Url Željko Prka (autor)

Avatar Url Ozren Jakšić (autor)

Avatar Url Marko Lucijanic (autor)

Avatar Url Vlatko Pejša (autor)


Citiraj ovu publikaciju:

Pejša, Vlatko; Prka, Željko; Lucijanić, Marko; Jakšić, Ozren; Piršić, Mario; Ajduković, Radmila; Kušec, Rajko
Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience // Abstracts of the Leukemia and Lymphoma Meeting "East and west are together"
Dubrovnik, Hrvatska, 2011. (poster, nije recenziran, sažetak, znanstveni)
Pejša, V., Prka, Ž., Lucijanić, M., Jakšić, O., Piršić, M., Ajduković, R. & Kušec, R. (2011) Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience. U: Abstracts of the Leukemia and Lymphoma Meeting "East and west are together".
@article{article, author = {Pej\v{s}a, Vlatko and Prka, \v{Z}eljko and Lucijani\'{c}, Marko and Jak\v{s}i\'{c}, Ozren and Pir\v{s}i\'{c}, Mario and Ajdukovi\'{c}, Radmila and Ku\v{s}ec, Rajko}, year = {2011}, keywords = {NHL, DA-EPOCH, high risk}, title = {Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience}, keyword = {NHL, DA-EPOCH, high risk}, publisherplace = {Dubrovnik, Hrvatska} }
@article{article, author = {Pej\v{s}a, Vlatko and Prka, \v{Z}eljko and Lucijani\'{c}, Marko and Jak\v{s}i\'{c}, Ozren and Pir\v{s}i\'{c}, Mario and Ajdukovi\'{c}, Radmila and Ku\v{s}ec, Rajko}, year = {2011}, keywords = {NHL, DA-EPOCH, high risk}, title = {Dose adjusted EPOCH – Rituximab as first line treatment for high risk, aggressive B-NHL : a single center experience}, keyword = {NHL, DA-EPOCH, high risk}, publisherplace = {Dubrovnik, Hrvatska} }




Contrast
Increase Font
Decrease Font
Dyslexic Font